News Agency
The Times

Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe Ulcerative Colitis

  • Written by PR Newswire

NEW YORK and SUZHOU, China, Sept. 20, 2026 /PRNewswire/ -- Accro Bioscience Inc. (Accro Bio), a clinical-stage biotechnology company pioneering the development of novel therapeutics for immune mediated diseases, today announced the dosing of their first patient in the Phase IIb clinical trial of AC-101, a selective RIPK2 inhibitor, in patients...

Read more: Accro Bioscience Announces First Patient Dosed in Phase IIb Study of AC-101 in Moderate-to-Severe...

How Can Businesses Reduce the Risk of Commercial Litigation?

Commercial disputes often begin with a misunderstanding, an unclear contract or a delayed response to a growing problem. Seeking early advice from Litigation Lawyers Sydney with PCL lawyers can help businesses trust and identify legal risks, clarify obligations and create a strategy... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion